Other languages Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
108,400 ^KRW	-1.09%		-1.99%	-7.19%

May. 14	Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	Apr. 24
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	Feb. 15
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	Dec. 10
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	Nov. 06
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	23-09-25
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	23-08-30
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US	23-08-02
Daewoong Pharmaceutical Enters into License and Distribution Agreement with Cooper Pharma	23-07-24
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	23-07-20
Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet	23-07-18
Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada Upon Termination of License Agreement with Neurogastrx	23-06-05
Avacta Group Plc acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd.	23-06-04
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023	23-05-19
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Daewoong pharmaceutical Co.,Ltd's Envlo to Enter the Global Market in Full Swing with Filing for Product License in Three Asean Countries	23-03-22
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08
M8 Pharmaceuticals and Daewoong Pharmaceutical Strengthens Strategic Partnership by Signing an Exclusive Licensing Agreement for Envlo (Enavoglifozin) for Brazil and Mexico	23-02-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Other languages

Filters